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Tm BIOLOGICAL EFFECTS of carrier-free radionuclides 
absorbed by the living organism are, with very few 
exceptions, a consequence of the ionizing radiation 
emitted. Accordingly, the therapeutic aim in cases of 
poisoning with metals will differ according to ~vliether 
the metals are or are not radioactive. If they are not, 
the conversion of the metal into an insoluble and thus 
pharmacologically inactive form or a change in its 
distribution Pattern can sometimes be taken as a thera- 
peutically satisfactory result; if on the other hand the 
metals absorbed are radioactive tlien the sole aim of the 
therapeutic measures taken must be tlieir removal from 
the organism. More precisely, the aim is to reduce the 
radiometal concentration primarily in tlie critical organ, 
that is to say the organ in which injury due to deposited 
radioactivity would be most serious for the organism. 
\Ire may say here that as far as most radiometals of 
practical interest or potential I-iazards are concerned, 
the critical orgaii is the skeleton. 
\Vheri tlle problem of radioactive poisoning and its 
treatment first aroused attentiori in view of tlie iilcreasing 
production and use of radioactive substances, no known 
complexing agent, or none at any rate that had been 
tested tr>iologically, had the qualities required to make a 
substance effective: namely, a suficiently broad thera- 
peutic range, inert behavior in metabolism, and, above 
all, a high affinity for the radiometals to be removed from 
the organism. Dimercaptopropanol (BAL), which had 
proved relatively effective in animal experiments and 
also in clinical tests in cases of poisoning with various 
stable heavy metals, failed generally against radiometals 
of practical interest (49, 50, 61), with the one exception 
of polonium-210 (43, 44). The first important advance 
was made with etliylenediaminetetraacetic acid (EDTA), 
which for a considerable time remained the only chelat- 
ing agent ivhicli had been at all extensively tested on 
animals and also sliowed favorable and encouraging 
clinical results (28, 62, 64). The earlier work on EDTA 
lias in recerit years been thoroughly surveyed (2, 6, 17, 
64, 67, 71), and there is no need to go over its results in 
detail here. However, it will be useful to outline briefly 
the potentialities, drawtjacks and limitations of the 
EDTA treatment. 
The activity spectrum of EDTA is rather restricted by 
the fact that, even under optimum conditions (of dosage 
and time of administration), it is ineffective or only 
partially effective against a number of radiometals of 
practical importance. It has more than once been 
established that EDTA cannot prevent the accumulation 
of radium, radiostrontium or radiobarium in the skeleton. 
Our  own experience (14) shows that it actually causes 
a 10-20 per cent increase in deposition, a fact which is 
consistent w i ~ h  Spencer's observation (77) on the 
inhibition of radiostrontium excretion in the urine in 
man after treatment with EDTA. EDTA also proved 
totally ineffective with ruthenium-106 (78). The  in- 
creased escretion of radioactive light lanthanides, such 
as cerium-I 44, is entirely attributable to a reduced 
deposition in the soft tissues, especially the liver; the 
fixation of cerium in the skeleton is either unaffected by 
EDTA or slightly increased (9, 10). Radioyttrium and 
plutonium respond fairly well to EDTA. But here we 
come upon the second disadvantage of EDTA: the 
marked dependence of its effectiveness on tlie time of 
administration. If EDTA is administered under condi- 
tions of dela?-ed treatment, that is a t  a time when the 
~najor  part of tlie radiometal has already been deposited 
in the tissues, the amount of radionuclide ~vhich can be 
mobilized is often small and witliout practical signifi- 
cance in relation to the remaining body burden. This 
is also true when the EDTA treatment is extended over 
prolonged periods, which in any case would seem to be 
a questionable procedure in view of the riephrotosic 
action of EDTA. 
These facts governed the direction and aim of subse- 
quent investigations: first, the analysis of factors generally 
relevant for biological effectiveness, and, secondly, the 
search for other substances more effective than EDTA 
and/or having a broader therapeutic range. Of Course 
these two problems are closely connected, since the 
prerequisite of a rational and systematic search for new 
pharmacologically effective compounds is a sound 
knowledge of tlieir mode of action. It was early recog- 
nized (42, 67, 7 1 )  that the effectiveness of a chelating 
agent is decisively affected t>y competition bet~veen the 
metal ion to be removed and natural body cations for 
the chelating agent. Provided the concentration of 
chelating agent in the organism is high, competition by 
trace metals present only in low concentrations can be 
ignored and further considerations are restricted to Ca 
ions and in some cases hydrogen ions. Without going 
more deeply into the theory (42), this means that the 
effectiveness of a chelating agent Z in regard to the 
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mobilization of a radiometal M should be related in a I .1 
first approximation to a quantity designated E: 
This holds good on the simplifying assumption that the 
radiometal is free from carrier, or at least has high 
specific activity, that the chelates of Z with biological 
trace metals can be ignored, and that at  physiological 
pH only simple I :  I Ca or M chelates are formed. The 
figure <r designates the proportion of the free anion Z-i 
in the total of all uncomplexed protonated species of the 
acid HiZ and is calculated from the acidity constants 
and the given pH: 
If information is availahle on the stability of the 
hydrogen and hydroxo complexes, the numerator in E 
should be multiplied by the distribution function y to 
obtain the total of all complexed M species; as a rule onlv 
slight and negligible variations of the E values are 
obtained as a result. Since at pH 7 for EDTA and its 
related polyamino acids oc is considerably smaller than 
K::~, the competition of hydrogen ions needs to be 
considered only at considerably lower pH values. Thus, 
for example, in acid urine a rather more marked break- 
down of the M chelates and-if the metal ions are re- 
absorbed in the tubules-a loss of effectiveness are to be 
expected. Moreover, extremely low pH values are found 
in the secreting cells of the stomach. Dudley (20) attrib- 
uted to a similar instability of the chelates the high 
concentrations of radioyttrium which he observed in the 
stomach wall after administration of the meta1 in 
chelated form. 
If the effectiveness of a chelating agent with various 
radiometals is considered in relation to the R ~ , / K ~ ,  
values, a satisfactory correlation is generally not ob- 
tained. Figure I shows the effectiveness of EDTA 
expressed as the radiometal content of the Organ after 
EDTA treatment as a percentage of the content of the 
organs of untreated control animals, for a number of 
carrier-free radionuclides under identical test conditions 
of dosage and time of administration of the EDTA. The 
lack of a clear relationship between the two variables 
was to be expected, because one relevant factor had 
hitherto been ignored, namely the competition between 
the therapeutic chelating agent and endogenous high- 
molecular chelating compounds (proteins, nucleic acids, 
etc.), ion-exchanging structures and, in some cases, 
hydroxyl or other anions for the radiometal. It is at 
present difficult to give even a semiquantitative treatment 
of these relationships because the appropriate acidity 
and stability constants are not yet known, nor is there 
sufficient information about the type of chelates involved. 
If a chelating agent is to have any effect on the biological 
behavior of a metal ion, then the p M  defined by E 
250 pM Ca Na,- EDTA 1.p. immediafe/y 
a h r  i K injecfion of radiomefals 
FIG. I .  Effect of EDTA undrr near optimal conditions on tlie 
retention of carrier-free radionuclides in the organs of tlie rat 
(Catsch et al. ( I  o, I 3, I 4) and unpublished resultsl. 
must at least he as great as or greater than the ph4 
determined solely by the biological milieu in the absence 
of Z, and the greater tlie difference between these t~vo  
pM values the higher the effectiveness should be. 
Since the concentration of competing endo, rrenous 
ions and chelating agents and eschange capacity of the 
ion exchangers is nearly invariant and since the tosicity 
of the chelating agent makes it impossible to increase 
the dosage at will, the therapeutic effectiveness can-at 
this stage in the discussion-he improved only by 
varying the quotient K $ , / K ~ ~ z ,  in other words, by the 
use of chelating agents which are significantly different 
in this respect from EDTA. There is no need to deal in 
detail here with the numerous chelating agents tliat 
have Ileen examined during the past few years and 
proved inferior to EDTA. In order to emphasize again 
the significance of the rtlativt chelate stal~ility defined 
by K;iz/K::z, we may l~riefly mention only I ,2-  
diaminocyclohexanetetraacetic acid (CIITA), whicli 
sl-iows substantially higher stability constants than EIIT.4 
for most metal ions, but only slightly different relative 
stabilities. Its biological effectiveness, whicli has so far 
been tested for plutonium (3, 73), radiocerium (10) 
and radioyttrium ( I  3), is thus in all respects comparable 
to that of EDTA and not superior to it. 011 tlie other 
hand, a particular group of polyamino acids were likely 
to be more effective than EDTA, and, as will be slio\vn 
later, tl-iis hypothesis was confirmed experimentally. 
These are substances with an alkylene bridge longer thail 
that of EDTA and interrupted by one or more atoms 
other than carbon. 
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X = 0: 2:~'-bis[di(carboxymethyl)amino]diethyl ether (BADE, 
B AET A) 
= C: 2:~'-bis[di(carboxymethyl)amino]diethyl sulphide 
(BADS) 










X = 0: I :z-bis[di(carboxymethyl)aminoethoxy]ethane (BAE) 
= S: i :2-bis[di(carboxyrnethyl)aminoethylthio]ethane (BASE) 
= N: triethylenetetraaminehexaacetic acid (TTHA) 
I 
COOH 
The reduction of chelate stability due to lengthening of 
the alkylene bridge and enlargement of the chelate ring 
is offset by the hetero-atoms (ether oxygen, sulfur or 
sutjstituted nitrogen) usable by the meta1 as ligand; 
most of the metals so far esamined have shown K~:, /K~3,  
values several log-units greater then EDTA ( I ,  5, 16, 
21, 41). 
The first substance of this group esamined was 
BADE, whicfi showed a stronger mobilization effect 
than EDTA for radiocerium, also in regard to its deposi- 
tion in the skeleton (g, 10). This also proved to be 
the case with plutonium (33), but not with radioyttrium 
(13) or thorium (34). A substance ~vith a considerably 
greater effectiveness and, in particular, a broader 
activity spectrum than the polyamino acids containing 
ether osygen is diethylenetriaminepentaacetic acid 
(DTPA). Table I shows some representative results 
obtained from experiments with rats, which show 
clearly the considerable differences in effectiveness 
between EDTA and DTPA, even under conditions of 
delayed treatment. It should be added that the favorable 
results obtained with plutonium have been fully con- 
firrned tjy other workers ( 2 5 ,  76), 'and that a greater 
effectiveness of DTPA as compared with EDTA is to be 
seen in the effect on iron (23, 24), chromium, cobalt, 
zinc (24), manganese (3 j) and uranium (8) toxicit).. 
Tlie dependence of chelating agent effectiveness on 
the quantity E should present a straight line in the 
log-log plot, provided a certain threshold value for E 
has been exceeded, that is, the affinity of the radiometal 
for endogenous chelating agents is less than its affinity 
for a chelating agent used therapeutically. From the 
TABLE I .  Effect of CaiIraa-DTPA und CalVa2-EDTA on 
Retention of Dzfferent Radioactive Metals in Rats 
I 1 ! 1% of Administered ~ o s e /  
Kef 
1 control - 
I EDTA !J2  minutes 
I DTPA 
control - 1 . 1  I 
EDTA I 7 t h ,  9th. i i th ,  13th 1 0.7 :z 
' DTPA day ! 0.4 38 1 
controi 8 - 142 I qo i 
EDTA \ . I DTPA , 2  minutes 
Ce141 ---- ---------- 
- ' I control j 136 : 2 5  
EDTX l5th ,  7th. 9th day i3: 1 :z ' ( 11 )  
I DTPA ; /  
U 1 control 1 : 60 ~ i . 5 t '  ., , , 
Th234 ( EDTA 1 1  i j 60 1 5 . 1  i(34) 
I 'frorn 2nd to 5 th  day I 43 i26 
DTPA ,,f 
- control 1 Q . I *  6.6*! 
control ' - 1 7.9 i 64 1 2.4t: 
EDTA :\6th, izth,  zist, mnd ,  I i 46 ' 6.7  (33) 
DTPA / 25th, 26th day , i .6 40 120 4 
--  -- ! --P ---- 
con t ro~  I 40 140 
DTPA I 6 hours 1 0  /9o ( 7 6 )  
DTPA 7th day 1 I 180 
I I 
* Per cent/gm of dry tissue. t Urine. 
definition of E it follo\vs that this straight line represents 
the dependence of effectiveness botli on the dosage of 
one particular chelating agent and on the relative 
chelate stabilities of a number of chelating agents. Thus 
the effectivities of two chelating agents having similar 
K values should overlap and, if adequate dosages are 
chosen, should behave identically. Figure 2 summarizes 
the corresponding data for radiocerium; four different 
polyamino acids (EDTA, DTPA, CDTA and HEDTA) 
were examined, six different dosages for DTPA being 
used. As regards skeletal effectiveness, it is possible to 
represent all experimental points within the limits of 
experimental error satisfactorily as a straight line, 
provided that E is greater than about 105. I t  should be 
stressed that with lower values for E the chelating agents 
induce a slight but statistically significant increase in 
radiometal deposition. The reason for this might be that 
the radiometal chelates are a t~ le  to diffuse into the 
extracapillary space and thus bring enhanced amounts 
of radiometal into contact with the competing ion- 
exchanging or -adsorbing structures of the bone. Assum- 
ing, moreover, that the competition of the bone tissue is 
more important than that of the high molecular chelating 
RADIOACTIVE METAL MOBILIZATION 209 
FIG. 2. Effect of several chelating asents and respective various 
doses of DTPA on the retention of CeIi4 in the organs of the rat. Ab- 
breviation~: DTPA-diethylenetriaminepentaacetic acid, EDTA- 
ethylenediaminetetraacetic acid, HEDTA-hydroxyethylethylene- 
diarninetriacetic acid, CDTA-I ,2-d~aminocyclohexanetetraacetic 
acid (Catsch and Le (10). Catsch, unpublished results). 
agents of the blood plasma, there must be a tendency 
towards increased deposition in the skeleton. As to 
effectiveness in the liver, the trvo lowest DTPA dos- 
ages of ~ o - ~  and ~ o - ~  mole,janimal show a definite 
deviation from linear regression. The fact that extremely 
low dosages of chelating agent are less effective than 
expected is not surprising in view of the fact that an 
important prerequisite for the validity of the dependence 
of effectiveness on E, namely a considerable excess of 
chelating agent over the concentration of radiometal 
and of biological trace metals, is lacking in this case. I t  
might be thought that appropriate extrapolation of 
these curves would throhv light on the E values necessary 
to obtain still greater mobilization. However, a certain 
caution seems indicated here in view of the fact that the 
postulated dependence of effectiveness on E leaves a 
number of relevant factors out of account and so implies 
a certain degree of over-simplification. Our  starting 
point hitherto has been that tlie behavior of the chelating 
agents hvithin the organism is completely inert, tliat is, 
they- are neither decomposed nor deposited but are 
within a short time excreted completely and unchanged. 
Tliis is indeed true for polyamino acids like EDTA and 
DTPA, as Foreman (24, 30, 32) has shown, but does not 
apply necessarily or unconditionally to other chelating 
agents of different chemical structures. 
The extent to which the efficiency Pattern depends on 
the metabolic behavior of the chelating agent is strikingly 
shown by the condensed phosphates, regardless of 
whether we think of these (like Graham's salt) as chelat- 
ing agents or, with Thilo (79), as soluble ion exchangers. 
As can be Seen from Table 2, the polyphosphates when 
administered early have a fairly strong effect on the 
behavior of various radiometals, deposition in the hone 
tissue being reduced as compared with EIITA, while 
the effectiveness in the parenchymatous organs is 
considerably less or indeed deposition may be actually 
greater (10, I 3, 73). Tests with polyphosphates labeled 
with P3' have shown (38) that they are present in the 
blood as nondiffusible and nonultrafilterable colloids 
and are deposited in the organs of the reticuloendothelial 
system and the kidneys. ~ h i s  also explains the increased 
deposition of radiometals in these Organs and the un- 
expectedly high skeletal effectiveness. The fact that the 
condensed phosphates do increase the excretion of 
radiometals from the organism is explained t>y the 
hydrolytic breakdown of the polyphosphates to lolver - .  
molecular poly- and metaphosphates, which can be 
excreted and have complexing properties (10, 73). Since 
the condensed phosphates have only a narroiv thera- 
peutic range and their effect in delayed treatment is 
negligible (IO),  they are of little practical importance. 
An unexpected result was also found d i e n  the higher 
homologue of DTPA, ten-dentate trietliylenetetramine- 
hexaacetic acid (TTHA) was examined, (Table 3). 
TTHA if administered early inliibits deposition of 
radiocerium and radioyttrium in the skeleton much 
more than DTPA. On extrapolation of the appropriate 
curve in Figure 2 this would correspond to an E value 
of the order of I O ' O  or 10". As regards effectiveness in 
the liver,' a reduction of the radiocerium content to less 
than 0.1 per Cent of the control would be expected, 
lvhereas, what \zre have in fact is a reduction merelj- to 
0.25 per Cent. As TTHA has a number oi' ligand sites 
greater than the coordination number of the radiometals 
concerned, we must assume the formation to some 
extent of bimetallic clielates and, in certaii-i circum- 
stances, of polynuclear aggregates, \vhicii could Iead to 
TABLE 2. Efect of n j  mg Sodium Pob$i~osf,hatu (Grai~am's 
Salt) on Ret~ntion of D~fferent Radzoactzu~ Af~tals in Rats" 
T of Control, Fiducial Limits (P = o 05) 
Radionuclide -- Ref 
I 
Liter ! Kidneys Skeleton 
Ygi  132 4j0 
(103-168) (198980) 
Geli4 23 250 
(20-16) , (182-345 
pu239 ; 82 189 
(57-107) (122-256) 




48 (10)  
(4l-j5) 
34 (73 ) 
(25-q3 ) 
and CeL4'. 10 miriutes 
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rABLE 3. Eftct of DTP.4 and TTHA on Dtstrzbution of 
Ce144 und in tlie Organs of tlie Rat* 
,' % of Control, Fiducial Limits (P = 0.05) 
Radio- 
nuclide Treatment I 
Lirer j ~ k e ~ e t o n  
- -- -P- 
i &PA alter 2 I .oz (0.78-1 3 0 ) ;  10.1 18.8-1 I . 6 )  
1 minutes ip 
T T H A a f t e r 2  (1.50(1.31-~.73)5.20(4.456.12) 
Cela4 minutes ip 
DTPA simultane- 10.1 I (0.08-0.14) I .28 (0.92-1.79) 
ously iv 
1 
TTHA simultane- 0 . 2 ~  (0.17-0.31 ) I  0.45 (0.33-0.62) 
i ously iv I I 
DTPA after 2 36 (27-49) 1 5.70 (5 .006.50)  
Ygl  ! minutes ip I 
, TTHA after 2 42 (31-60) 1 3.27 (3.21-4.37) 
minutes ip 
* Dosages: 250 PM CaNa,-DTPA ip,  ICQ PM CaNa3-DTPA 
i v ,  250 MM CaNa4-TTHA ip ; IOO PM Ca zNa4-TTHA iv (Catsch 
8: Schindewolf-Jordan, unpublished results). 
behavior similar to that of the colloidal condensed 
phosphates. A deviation in the behavior of TTHA was 
also established in the Course of our investigation (8) 
into tlie influence of various chelating agents on the 
acute toxicity of uranyl nitrate: when a single dose of 
the chelating agent is administered early, the LDSo of 
uranium is increased from 6.7 mg/kg to 12.4 mglkg by 
EDTA and to 16.2 mglkg by DTPA. On the other hand 
TTHA, the toxicity of which is norrnally no different 
frorn that of EDTA or DTPA, was IOO per cent lethal 
to uranium injected animals, and, actually, within one 
hour of administration. \Ye attributed this potentiation 
of TTHA toxicity by uranium to the formation of 
insoluble polynuclear uranium chelates in the blood. 
With regard to the figures given in Table 3, which show 
a clear increase of effectiveness as against DTPA, we 
feel that this substance calls for further investigations, 
which should also include plutonium. 
To deal with the question of the dependence of 
effectiveness on the quantity of E, any deviations frorn 
linear behavior can be explained on different principles 
frorn those discussed earlier. There would seem to be 
some grounds for assuming that a given organ does not 
behave as a hornogeneous unit in the absorption of 
radiometals, but rather as one composed of several 
compartments differing in affinity for radiometals and 
so, also, in the ability to mobilize the radiornetal by 
means of chelating agents. Figure 3 shows schematically 
how the assumption that the organ consists of two 
compartrnents with different affinities for a radiometal 
and thus, also, different threshold dosages for E results 
in a nonlinear relation between effectiveness and E for 
the organ as a whole. 
Let us now turn to radiostrontiurn as a special case. 
Here DTPA proved just as ineffective as EDTA ( I  4, 51 ) ; 
cornparable experiments on radiobarium and radium 
have still to l ~ e  made, but it can be presumed with fair 
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FIG. 3. Hypothetical dependence of the effectiveness of a chelat- 
ing agent on the value E (see p. 207) under the assumption that 
the organ is subdivided in two distinct compartments characterized 
by a different affinity towards the radiornetal. 
total failure, or at txst only slight effectiveness, of all 
chelating agents so far tested with radiostrontium is not 
fortuitous (as Schubert (68) has recently shown again in 
detail). Rather it is an expression of the general rule 
that chelate stability constants are inversely proportional 
to the ion radius of the alkaline earth atoms, in other 
words, that the competition of the Ca ions for the chelat- 
ing agent will be notably stronger than in the case of 
other radiometals. I t  must be granted that the difference 
between the Ca and Sr stability constants of EDTA and 
DTPA, of some 2 log units, is exceptionally large, and 
that it is not difficult to find chelating agents with E 
values only a little below I .  But the effectiveness of these 
is still disappointingly low, the reduction of radio- 
strontium deposition in the skeleton being 10-20 per 
Cent on early administration. Individual chelating agents 
which have been shown to have some, if only slight, 
effectiveness are sodium citrate (7, 14, 45-47, 70). 
tricarballylic acid (45-47). sodium thiosulfate ( 1 5 ) ~  
pyrocatecholdisulfonic acid (14, 51). 10"- and high- 
molecular meta- and polyphosphates (7, 14), BADS 
(14) and BADE (14, 53). Since rhodizonic acid is a 
selective precipitating agent for strontium, Lindenbaum 
and Fried (55) examined its effect on the distribution of 
carrier-free radiostrontium but found it relatively slight. 
This, moreover, was not confirmed by other investigators, 
admittedly working under somewhat different experi- 
mental conditions (51, 57, 81). So far the greatest 
reduction in radiostrontium deposition in the skeleton 
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,ABLE 4. Effert of BADE (BAETA) snd BADS on Skeletal 




1 (P = 0 05)  
250 PM Na?-BADS simultaneously 
250 PM SrNaz-B.4DS simultaneously 
500 PM SrNaz-BADS simultaneously 
IOO PM Na?-BADE simultaneously 
ioo PM SrNaz-BADE simultaneously 
30 PM SrNa ?-BADE simultaneously 
250 PM SrNaz-BADE simultaneously 
500 PM SrNaz-BADE simultaneously 
500 ,UM SrNnz-BADE after 2 hours 
500 PM SrNa2-BADE after 24 hours 
(to 35 per Cent of the control) has heen obtained with 
Diamond Fast Blue (51); but siirice this dyestuff in 
effective doses has proved strongly toxic and sometimes 
lethal it has not an. practical importance. 
\Ve cannot confirm Schubert's assumption (70) that 
the removal of radiostrontium by means of zirconium 
citrate is governed exclusively by the citrate component 
since we have shown (14) that zirconium citrate is defi- 
nitely more effective (with a reduction to 65 per cent) 
than sodium citrate (80 per cent). According to Kroll 
(53) BADE sho~vs a greater effectivity when used in the 
form of the Sr chelate, that is to say, the effect of the 
cheiating agent is combined witli that of an isotopic 
dilution of the radiostrontium. Table q shows that we 
were able to confirm that the effectiveness of Sr-BADE 
was greater than that of Xa2-BADE, though still inade- 
quate, especially if it was administered several hours after 
radiostrontium. Naturally a low mobilization effect is 
better than none at all; but the results obtained so far 
are so insignificant (compared with those obtained by 
DTPA with other radiometals) that in my estimation 
there is at present no occasion to revise the generally- 
pessimistic assessment of the therapeutic possibilities for 
radiostrontium poisoning; especially as the chances of 
finding a chelating agent ~16th considerably higher 
relative stability or, indeed, with a selective affinity for 
strontium are extremely slight. There is the additional 
fact that the effective substances mentioned above 
prove ineffective if administered after a delay. Their 
ineffectiveness in delayed treatment is attributable 
mainly to the fact that the radiostrontium which is 
initially reversibly bound on the surface of the apatite 
crystals is relatively soon removed from the equilibrium 
as a result of the onset of recrystallization and is con- 
verted into a form which is no longer accessible to the 
chelating agent (60). 
Since heavy metals of the sixth period prefer sulfur to 
oxygen as ligand atom, it seemed useful to include 
suitable substances in our tests. In conformity with the 
only slightly differing K;kZ/KC;, values of EDTA and 
DTPA both these chelating agents showed no significant 
variations of effectiveness either on early or delayed 
administration; Fried et al. (37) obtained the Same result 
in exploratory toxicity experiments. Polyamino acids, 
which contain ether or thioether linkages, also showed 
no increase of effectiveness over EDTA. It should of 
Course be mentioned here that sulfur in the form of 
thioether is in principle a much weaker coordination 
Partner than in the form of merca~t ide or sulfite. The 
only polyamino acid which gave us a definitely stronger 
mot>ilizatioii of radiolead than EDTA was cystamine- 
tetraacetic acid (CyTA). It  is not yet clear whether 
CyTA is effective in itself or only after splitting of the 
disulfide bond, that is, in the form of the resulting 
mercaptoethyliminodiacetic acid. This latter assumption 
would seem to be supported by the toxicity of CUT-4, 
which is about ten times highcr than that of other 
polyamino acids and appears, primarily, in damage to 
the kidnevs. The stabilitv constants for the Pb-CvTA 
chelate have not yet beeb established, though tha; for 
mercaptoethyliminodiacetic acid is known (4). .4ssuming 
a complete splitting of the CyT.4 in the organism, and 
considering the effectiveness in relation to the E values 
for various dosages of mercaptoethylirninodiacetic acid, 
EDTA and DTPA, we get (as shown in Fig. 4) a satis- 
factory linearity within the limits of experimental error 
in the case of the liver and kidneys. .4s to the skeleton, 
CyTA proves considerably less effective than its behavior 
in the other organs might have led us to expect, the 
slope of the straight line obtained for various dosages of 
CyTA being apparently identical with the slope repre- 
senting the effectiveness of various dosages of EDTA 
and DTPA. T o  explain this discrepancy we mau assume 
as a working hypothesis that the splitting of the disulfide 
bond of CyTA occurs preferentially in the liver and 
kidneys, or that the &ercaptoethylirninodiacetic acid 
has a specially high affinity for these organs. Results so 
far do not suggest that CyTA is of practical importance 
since its effectiveness in nontoxic dosages is of the Same 
order as that of EDTA and DTPA. 
The first results of experiments still in Progress with 
carrier-free mercury-nog are shown in Figure 5. The 
only organs whose mercury content is affected by 
polyamino acids, and that only to a slight estent, are 
the kidneys. The graph connecting effectivity and the E 
values shows, in this case, only a negligible slope and a 
marked scattering of tlie points. One has the impression 
that it is the linger-chain polyamino acids that are 
considerably less effective than would have been ex- 
pected from their E values. The reasons for this escep- 
iional behavior are not yet clear; it is pocsible that the 
substances in question behave differently- from the other 
polyamino acids in metabolism. The polyamines which 
\ve also examined were completely ineffective in spite of 
very much higher E values, which is most probably due 
to their metabolic breakdown. As with radiolead, CyTA 
proved the most effective, the mercury content of the 
kidneys beirig reduced, under identical test conditions, 
to about 25 per Cent of the control, although a much 
slighter effect might have been expected from the E 
value of xo8 (on the assumption that the mercapto- 
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FIG. 4. Effect of various doses 
of several chelating agents on the 
retention of Pb210 in the organs 
of the rat. I t  is assumed that 
CyTA (cystaminrtetraacetic acid) 
is completely split up into 2-  
mercaptoethyliminodiacetic acid 
(Catsch, unpublished reeults). 
ethyliminodiacetic acid is the effective substance). I t  is 
interesting that other chelating agents with fewer ligand 
sites, such as iminodiacetic acid and ethylenediamine- 
S,Xf-diacetic acid were effective to a relatively high 
degree. As Figure 6 sliows, the effectiveness of CyTA 
when administered after a delay increased, in contrast 
to  what happened with other chelating agents and other 
radiometals. I t  was stated a t  the outset that both toxicity 
and excretion of polonium-210 are favorably affected by 
BAL (43, 44) or its water-soluble sulfonic acid derivatives 
(22). Ko  comparison has yet been made between the 
sulfhydryl compounds and DTPA or other polyamino 
acids. 
The high effectiveness of DTPA, which is evident 
even at  relatively low dosages, makes it possible to 
analyze its action in more detail than is possible with 
EDTA. Table r sliows that the greater effectiveness of 
DTPA (as against EDTA) is maintained when it is 
administered after delay, but that the dependence of 
effectiveness on time is again unmistakable. T o  explain 
this generally valid circumstance a factor which has 
heen ignored hitherto must now t>e taken into account, 
namely the rate at  which the chelates are excreted from 
tlie organism. The high effectiveness observed on 
administration of the chelating agent immediately or 
\cithin a sliort time is partly due to the fact that the 
freely diffusible metal chelate is excreted rapidly by the 
kidneys and thus is to a large extent withdrawn also 
from the competition of the endogenous chelating agents 
arid ion exchangers. If a chelating agent is removed 
comparatively slowly from the blood, t h e  partition of' 
the metal chelate l~etween excretion and intercellular 
space is shifted in favor of the latter, and in the light 
of the ideas discussed above we should expect a reduction 
of effectiveness. That  this assumption is correct has been 
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FIG. 5 .  Effect of several chelating agents on the retention of 
Hgzo3 in the kidneys of the rat. HMDTA-hexamethylenediaminr- 
tetraacetic acid; for further abbreviations See p. 208 and legend 
of Fig. 2 (Catsch and Nigrovi6, unpublished results). 
impressively shown in a test carried out by Semenov 
et al. (72): Carrier-free radioyttrium was injected with 
an  excess of EDTA into nephrectomized rats and the 
radioyttrium content of the organs was measured after 
24 hours. The distribution differs hardly at  all from that 
in the control animals kvhich were given only radio- 
yttrium. I t  should be rnentioned that the blood con- 
centration of the EDTA labeled with C1"emains 
constant over the same period of time in the case of the 
nephrectomized animalc (32). This sholvs that as soon 
as the excretion factor is removed the stability of the 
Y-EDTA chelate is no longer sufficient to compete 
successfully with the tissues. 
If a chelating agent is administered when the bulk of 
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FIG. 6. Effectiveness of DTPA and CyTA (50 pM per rat and 
dose) in removing HgZo3 from the kidneys of the rat (Catsch and 
NigroviC, unpublished results). 
the radiometal is already deposited in the tissues and 
organs, its effectiveness depends in the first place on the 
relationship defined above between the \,arious com- 
plexing affinities and also on the chelate excretion rate, 
which, however, here has the opposite effect to that 
discussed above. Mobilization of the radiometal de- 
posited in the tissues is in principle possible only through 
chelation of the free metal ions and the consequent 
disturbance of the equlibrium with the cellular chelating 
agents or ion exchangers. If the rates at which the 
endogenous chelates decompose and/or the metal ions 
flow into the extracellular space are slow in relation to 
the rate of excretion of the chelating agent, then the 
effectiveness of the latter must decrease fairly rapidly. 
Provided a chelating agent is effective at  all, that is, it 
exceeds the threshold value for E for the radiometal 
concerned, its effectiveness should be inversely propor- 
tional to the excretion of the chelate. The significance of 
the solubilizing rate may be exemplified by the findings 
of Schubert and Fried (69): the dissolution of an olated 
thorium hydroxide by means of DTPA in vitro is ex- 
tremely slow in spite of the very high stability of the 
Th-DTPA chelate. The same thing occurs in vivo; if 
animals are injected with colloidal thorium hydroxide, 
excretion is only slightly intensified by repeated doses of 
DTPA, whereas if monomeric thorium citrate is injected 
the effectiveness of the DTPA becomes very marked 
indeed. The reduced effectiveness of chelating agents 
with certain isotopically diluted radiometals [e.g. 
radioyttrium ( 7 2 ) ]  is also attributable to the slow 
solui~ilization of the colloidal metal aggregates. 
The excretion of radiometals from the various organs 
as a rule represents a multiexponential function in ~vhich 
the individual terms formally can be assigned to particu- 
lar compartments which presumably possess different 
affinities for coml~ination with the radiometal. Here it 
is of course a prerequisite that individual compartments 
are not interchangeable or that the appropriate rates of 
interchange are low in relation to the excretion rate. 
Since the mobilizing capacity of a chelating aqent 
depends essentially on the stability of the endogenous 
radiometal complexes, it follo~vs that the effectiveness is 
inversely proportional to the so-called biological half- 
time, and should decrease in the event of a multi- 
exponential excretion function, indicating the progressive 
increase in the significance of the "slow" components 
with the passage of time. These suppositions were con- 
firmed by tests with radiocerium, whose excretion from 
the liser during the first two months after administration 
can be expressed as the sum of two exponential terms 
with half-time values of 5 and 15 days, respectively, in 
rats. The "fast" component is predominant, that is, 
during the first four weeks, the effectiveness of single 
dosages of DTPA remains roughly constant, giving a 
fall in radiocerium content to about 53, regardless of 
the time of administration (Table 5). It decreases only 
\\,hen the "slotv" component is predominant. This is 
also the case when the readily mobilizable fraction of 
the radiocerium, corresponding to the "fast" component, 
has been removed by a previous dosage of DTP.4, so 
that the effects of several successive DTPA dosages are 
no longer fully additive (Catsch, unpublished results). 
For the reasons already discussed in connection w i ~ h  
radiostrontium, the progressive decrease in effective- 
ness in the skeleton is especially strongly marked. 
Examination of the distribution over the various sec- 
tions of the femur has s h o ~ n  that radiocerium de- 
posited in the metaphysis is mobilized bl- DTPA to 
a greater extent than from the epiphysis and diaph- 
ysis (Table 6). I t  can also be seen that here the pro- 
gressive loss of effectiveness is more strongly marked, 
as \vould be expected given the exceptionally intensi\.e 
growth processes taking place in the metaphysis. These 
results were obtained with young rats, and it may be 
asked whether the dependence of effectiveness on time 
~vould be as great if the animals were fully grown. 
Another factor which is still not clear is the effectiveness 
of chelating agents where the administration of radio- 
metals has been maintained over a prolonged period, 
the result of which, as compared wit11 a single dosage, 
is to give a much more uniform distribution of the 
radiometals in the skeleton. 
The differences in the extent to which the radiometal 
in the liver and skeleton can be depleted by DTPA were 
shown by Fried et al. [quoted in (6j)I for plutonium 
als3: daily administration of DTPA over two weeks re- 
duced the plutonium content of the li\.er to 3 per cent of 
the control, while that of the skeleton fell only to jo per 
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TABLE j. Dependence of tlie CaXa3-D T P A  Efectiveness in 
Remouing Ce'" from tfre Organs of Rats 
on tlze Time of its Administration* 
7, of Control, Fiducial Limits (P = 0.05) 
I>a> of Administration j- , 
I Liver Ridneys 1 Skeleton 
I 
* Single ip dose: 250 (Catsch, unpublished results, and 
Catsch gr Le (11 j). 
TABLE 6 .  Effect of C a S a 3 - B T P A  on Retention of Cf'" in 
Dzfercnt Parts of tfre Rat Femur* 
1 % of Control, Fiducial Limits (P = 0.05) 
Time of Injection 
After Ce144 ! 
Epiphysis ) Metaphysis I AIidshaft 
- - 
1 
2 minutes 1 14 (11-17) g (7-11) ' 12 (1e14)  
5th day 87 (70-108) ' 64 (50-82 ) 1 82 (70-97 
5th, jth, 9th days 1 7 1  (58-86) ! 46 (40-53) 72 (55-87) 
25th day 1 90 (80-100) i 85 (63-115) 1 90 (70-115) 
I 
* Single ip dose: 250 (Catsch 8r Schindewolf-.Jordan, un- 
published results). 
Cent. Tests by Foreman (25), in which administration of 
DTI'A was t~egun one month after administration of 
plutonium and was continued over various periods of 
time, also suggest that the effectiveness of DTPA was 
pretty well exhausted after a four-week treatment. 
As to its effectiveness in man, we have so far only the 
observations of Norwood; in some cases, where the 
incorporation of plutonium took place several years 
previously, DTPA gave a considerably more (about 10 
times) intensified excretion as against EDTA. 
Absorption of DTPA from the gut is low (as with 
EI)TA) and represents about 4 per Cent of the total dos- 
age (24). Provided the dosage is sufficient the fraction 
absorbed should be enough to show a clear effect. The  
effectiveness of DTPA administered orally has been 
esperimentally shown for radiocerium (12) and in a 
particularly impressive manner by Foreman [quoted in 
(6 j)] for americium-241 . 
In contrast to the previously accepted view that the 
excretion of radiometals mobilized by polyamino acids 
is effected only by the kidneys, it has been shown that 
DTPA causes a marked increase in radiometal excretion 
in tlie feces, especially in the case of those which, like 
radiocerium, are deposited to a large extent in the liver 
(Fi?. 7) .  After a single dosage of DTPA, for example, 
on the fourth da)- after administration some I I per Cent 
of radiocerium (above the control excretion rate) was 
excreted in the urine and 2 0  per Cent in the feces. Because 
the fecal excretion rate nf radiocerium is naturally high, 
the factor by which the pretreatment excretion level is 
increased by DTPA is considerably higher in urine. The 
'" 1 275,uM CaNa+DTPA on 5th day I 
" 5  6 7 5 6 7days 
urine feeces 
FIG. 7. Effect of a single DTPA dose on the excretion of Ce14" 
from the rat (Catsch and Le (1 I ) ) .  
proportion of radiocerium mobilized by DTPA and 
excreted in the urine and feces is about I :I, which is 
surprising in view of the fact that the corresponding 
proportion of excreted C1"labeled DTPA is about 
16: I (24). 
DTPA gave unexpected results in other respects as 
well. Earlier work (18, 72) had shown that EDTA is 
still effective when administered three hours before the 
administration of radioyttrium. In  regard to the clear 
effectiveness of relatively small dosages of DTPA (cf. 
Fig. 2) a prophylactic effectiveness might be expected at 
even longer intervals of time and has in fact been 
established experimentally ( I  2): 250 DTPA per rat, 
injected I 2 hours before administration of radiocerium, 
reduced deposition of the latter in the skeleton to about 
50 per Cent and in the liver to 3 per Cent of the control 
values. In this case the very pronounced liver effective- 
ness is surprising. According to Foreman ( q ) ,  after 12  
hours some 0.03-0.05 per Cent of the total Ca-DTPA dos- 
age is still present in the blood. This would in our experi- 
ment be equivalent to a dosage of about 0.1 from 
which, however, on the basis of the results discussed above 
(cf. Fig. 2),  one would have expected the liver content to 
fall to not less then 10-20 per Cent of the control value. 
From the earlier work on EDTA it was assumed that 
the enhanced excretion, in keeping with the rapid and 
complete excretion of EDTA, was limited to a fairly 
short period, about the first 24 hours. Fried et al. (33) 
however showed that plutonium clearly continued to be 
excreted in the urine in more than normal quantities 
several days after administration of DTPA. Our own 
tests with radiocerium had given the Same results (Fig. 
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thus only apparent, because the mobilization of radio- 
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FIG. 8. Effect of a single DTPA dose given on the ist day on the 
Ce14* content in the liver of the rat (Catsch, unpublished results). 
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FIG. g. Effect of a single DTPA dose given on the ist day on the 
Ce'44 content in the skeleton of the rat (Catsch, unpublished re- 
sults). 
0 
8, 9):  after a single dose of DTPA on the first day the 
liver shows a progressive decline in radiocerium content 
which continues over at  least five days, and only on the 
eighth day does the effectiveness of DTPA appear to be 
exhausted, as thenceforward the curve runs parallel to 
the excretion curve of the untreated controls. In the 
skeleton the decrease is definite even after the eighth 
day. Here, of course, it is questionable whether this is 
due solely to the DTPA, and we suggest the following 
explanation: we know that a certain fraction of the 
radiocerium initially deposited in the liver returns to 
the blood stream and is absorbed into the skeleton. The 
constancy of the radiocerium content in the skeleton is 
cerium from the bones is to a large extent compensated 
by this redistribution, and cannot be observed until this 
factor has been removed, that is, after the radiocerium 
content of the liver has been reduced hy DTPA. 
The somewhat unexpected results discussed above- 








feces, the surprisingly prolonged or high effectiveness 
after a single or prophylactic dosage of DTPA-seem to 
call for some revision of the accepted views on the 
behavior of polyamino acids in the organism. Since the 
Ca chelates of polyamino acids are water-soluhle and 




they \irould be able to penetrate cell membranes and 
enter the intracellular space to any great extent. This 
assumption was supported by the work of Foreman (24) 
on the behavior of Ca chelates labeled with Cl4. Our o\vn 
observations on the other hand could well be explained 
by the assumption that a fraction of the Ca-DTPA 
chelate. minor indeed but still effective. tends to con- 
centrate in the intracellular space, at any rate, of the 
liver. 
This tentative hypothesis is also favored by other 
observations that are not in a strict sense proof positive 
and only indirect: in the first place, the DTPA concen- 
tration in the liver 24 hours after administration is 
clearly higher than that in the blood (24). Studies b> 
Lindenbaum and Schubert (56) on tissues from animals 
given plutonium show that tlie ultrafilterabi1it)- of 
plutonium present in the tissues is increased followiny a 
single DTPA dosage and that this persists for at least a 
week. The information given does not of course show 
how the organ homogenates examined were obtained 
and prepared, so that the increased diffusibilit!. of the 
plutonium could naturally be due also to traces of DTPA 
in the extracellular space. Our own work on radiocerium, 
in which the liver was thoroughly and ver)- carefully 
perfused in situ before being liomogenized, gave the 
Same result: 5-12 per Cent of the total amount of radio- 
cerium contained in the liver homogenate remained 
freely dialyzable during the first five days after admin- 
istration of the DTPA, tihereas in the untreated control 
animals this fraction was practically nil. 
IYe may also mention the results of work still in 
Progress, which deals \vith the effect of DTPA on tlie 
intracellular distribution Dattern of radiocerium. A 
state of equilibrium, that is a constant distribution of 
radiocerium over the various subcellular fractions of the 
liver homogenate, is reached only some days after the 
injection of radiocerium; during the first fe\v days the 
protein-free fractiori of the cytoplasm sliows a fairly high 
and slowly decreasing radiocerium concentration, while 
tliat of the cytoplasm proteins and of the cellular or- 
ganelles increases not only relatively but absolutely 
over tlie same ~ e r i o d .  It  can thus be assumed that the 
supernatant obtained after precipitation of tlie cytoplasm 
proteins represents the quickly reacting cell fraction, 
and that the transfer of the radiocerium into the other 
subcellular fractions andior its complexing by tlie 
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appropriate constituents take place relatively slowly. 
On the assumption that the Ca-DTPA chelate is present 
only in the extracellular space, it would be natural to 
expect the administration of DTPA to be followed by a 
reduction of radiocerium content of the protein-free 
cytoplasm fraction, at the very least equivalent to that 
in the slower reacting fractions. However, Figure I o 
sliows that in fact the opposite is the case: the radiocerium 
concentration of the cytoplasmic supernatant is clearly 
relatively higher during the first fe\v days after admin- 
istration of DTPA as compared with the other fractions, 
and shortly after administration is absolutely higher. 
This observation, together with the evidence obtained 
by electrophoresis for the presence of Ce144-DTPA in tlie 
cytoplasm, favors our assumption that a small fraction 
of the DTPA is present within the cell for a fairly long 
time. At present \ve are trying with the lielp of auto- 
radiographic investigations to show direct aridence of 
the presence of DTPA labeled with Cl4 in the cell. I t  
seemed to me necessary to discuss more closely these 
observations, whicli at first sight seemed of only theoreti- 
cal interest, because (as \tri11 he shown later) it afforded 
starting points of practical importance for further 
development. 
The polyamino acids are as a rule administered in 
the form of their Ca chelates, ~vhich are onl>- slightll- 
toxic. As the free sodium salts give rise to some de- 
mineralization of the skeleton and as sufficient clinical 
experience is available to show the tolerance for Ka2- 
E l lTA \vhen slowly administered intravenously, the 
0 7 2 3 4 
days - 
FIG. I o. EfTect of a single DTPA dose given after 2.5 hours on the 
Ce"' content in the subcelIular fractions of the liver homogenate 
(Catsch and Immel-Teller, unpiiblished results). 
question arises \vhether use can be made of this to im- 
prove the effectiveness of the clielate. Cohn et al. (18) 
thought that the relatively effective mobilization of 
radiGttrium from the skeleton observed by them could 
be attributed to the alternating administration of 
CaKa4- and Ka2-EDTA; there are no controls in this 
case, so that this conclusion does not seem justified as 
yet. Semenov and Tregubenko (72) have recently dealt 
in detail with tlie same question anci were able by means 
of repeated doses of Na2-EDTA to reduce the radio- 
yttrium content of the skeleton to 64 per Cent of the con- 
trol, whereas CaXa2-EDTA reduced it only to 80 per 
Cent. However, both forms of EDTA proved equally 
effective as far as the parenchymatous Organs were con- 
cerned, which is what \vould be expected. This observa- 
tiori is not hoivever amenable to generalization and it 
was impossible to reproduce it with other radiometals 
such as cerium and plutonium. 
-4ttempts to increase the effectivity of chelating agents 
by simultaneous administration of diuretics, the cholago- 
gue dehydrocholic acid or parathormone ( I  I ,  14, 39, 
7 4 ,  \vhich intensify the bone resorptiori processes, have 
proved negative or unconvincing. A clear increase in the 
effectiveness of EDTA, howver, was obtained in the 
mobilization of lead from the bones by combining it 
with vitamin A (jg), which in massive dosages is known 
to enhance bone resorption. 
A fundamentally different starting point for improving 
the therapeutic effectiveness of chelating agents is to be 
found in the observations already discussed in detail 
concerning the distribution of chelating agents in the 
extra- and intra-cellular space. In  our view there are 
certain indications which suggest that the high effective- 
ness of DTPA is to a certain extent due to its penetration 
into the intracellular space, particularly in the liver; 
and it was therefore natural to expect that if this process 
were intensified there would be a corresponding increase 
in effectiveness. This possibility had already been 
discussed by Fried et al. (36) and even verified experi- 
mentally: b>- administering fluoroacetic acid, these 
authors were able to reduce the toxicity of nonradio- 
active Iead by a factor of about 1.15. The mode of 
actiori of fluoroacetic acid is supposed to be that, as a 
metabolic inhibitor, it interferes with the Krebs cycle 
and leads to an intracellular accumulation of citrate, 
which is known to have a fairly high affinity for lead 
ions. The stability of the citrate chelates with the radio- 
metals of practical interest to us is however too low to 
suggest that this principle could be satisfactorily- applied 
in this case. 
Another approach that seemed more promising was to 
use chelating agents with a high intrinsic permeance, 
for example esterified polyamino acids. By esterifying 
the carboxyl groups, the ligand groups necessary for 
chelation were, it is true, blocked, but it was reasonable 
to expect that the esters would be hydrolyzed at  the 
intracellular pH, perhaps with the assistance of esterases, 
and that the effective ligand groupings would be lib- 
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H O O C - H ~ C ,  ,C+-COOH H ~ C ~ O O C - H  C ,cn2-c=o TABLE 7. Efect of H E D  T A  and DOC,  ildmznzstered after 24 
N - C H ~ - C H ~ - N ,  ' N - C H ~ - C H ~ - N  , > O  Hours as Calcium Sodzum C/ielatr (C / ! )  or Hespectir!~ Ester 
H O O C - H ~ C '  C H 2 - C H 2 0 H  H 5 ~ 2 ~ ~ ~ - ~ ~ ~ /  CHZ-CH2 Lactone ( E ) ,  on Distrzbutzon of Gel44 and 
N'-(z-hydroxyethyl)ethylenediamine-N,N,N'-triacetic acid -- 
17" Zn tlir Organs of tlie Rat* 
(HEDTA) and derivati~e. "; of Control. Fiducial Limits iP = o o;) 
fz\g Treatment 
COOH HOOC 
I Lirer Kidneys Skeleton 
P- ~ -- P- 
HEDTA-Ch iv 198 (93-103) 90 (84-97 ) 99 (93-105) 
HEDTA-E iv 76 (73-79) 94 188-101 ) 1 0 2  (97-107 ) 
C e l 4 9 E D T A - E  po 79 (73-86) i 12 (9G130) 106 (96-117 )
OH HO DOC-Chip 87 (75-100)1wj(72-147)  98(84-115)  
DOC-E ip (68 (59-79 91 (63-730) 93 (79-109 1 
N,N'-bis (2-hydroxycyclohexy1)ethylenediamine-V'-  
diacetic acid (DOC). 
Among compounds which we have so far examined is the 
ethyl ester of HEDTA, which exists partly in a lactone 
form, and thus is a so-called inner ester. The compound 
is water soluble at p H  7 and is readily admini'stered 
intravenously. The  corresponding free polyamino acid, 
HEDTA, is a chelating agent comparable with EDTA 
9, 13) in biological effectiveness. Also water soluble 
a t  p H  7 is tlie second compound examined by us, DOC, 
which occurs as a dilactone. As a control D O C  was 
administered in the form of its CaNaz chelate which was 
prepared by hydrolyzing the lactone at  p H  10 and jo°C 
and then adding an  equimolar amount of Ca. Table 7 ,  
which summarizes the exploratory tests, shows that 
bot11 esters 24 hours after intravenous iniection of 
radioyttrium or radiocerium effect a clear mobilization 
of tlie radiometals from the liver, while the corresponding 
Ca chelates have no significant effect. An approximately 
cquivalent effect u7as observed when the ethyl ester of 
HEDTA was administered orally. That  the ester lias no 
effectiveness in tlie skeleton is consistent witli the t~asic 
suppositions about its mode of action. That  no clear 
effect \ras established in the kidneys does not quite 
justify the conclusion that the esters are selectively taken 
up  by the liver cells and; or are hydrolyzed 11) them. 
The  results mentioned earlier had shown that radio- 
cerium deposited in the kidneys is fairly quickly con- 
verted into a form that is difficult to mobilize (see Table 
5). I n  the light of the observation that fecal excretion is 
intensified by the DTPA-present, as assumed, in the 
intracellular space-this was also to be expected in the 
cace of esterified polyamino acids and was establislied 
experimentally (Fig. I I ) .  The  reduction of ttie radio- 
meta1 content of the liver by some 30 per Cent by the 
esters is in these circumstances rather low and not 
comparable with the effectiveness of DTPA, wliich in all 
prol~ability is connected with tlie inadequate relative 
stability of the HEl lTA and DOC chelates. These 
observations are, therefore, at  present of practical 
importance only to the extent that they indicate a 
fundamentally new approach to the therapeutic use of 
clielating agents. Final conclusions can naturally only 
be drawn when we know something about the esters of 
more powerful chelating agents, such as DTPA 
Hitherto we have been concerned solely with tlie 
--- ------ ------ 
Y9' HEDTA-Ch iv 9 4  (80-1 I I ) 98 (77-129) 90 (85-96) 
HEDTA-E iv 67 (56-79) I 14 (87-150) 96 (91-101 
* roo MM HEDTA, 250 p M  DOC (Catsch). 
' after 2Vhr 
FIG I I . Effect of a sinqle HEDTA-ester dosr on the rxcretion of 
Ce'14 from the rat (Catscli, unpiiblishrd rrsiilts) 
removal of radiometals alreadp deposited in thr Organs 
or-under optimum conditions-still in the blood stream 
at  tlie time when the chelating agent was administered. 
This leaves out of account a point of practical impor- 
tance, namely tlie way in wliich contamination occurred. 
The esperience of tlie past few years (28, 29, 34, 64) 
has shown that the inhalation of radioactive material 
and contamination of wounds are in practice 1)y far thc 
commonest ways. If the radiometals entering the body 
in this ~2.a)- show only a slight absorption rate and if iri 
the case of contaminated wounds the radioactive deposit 
cannot be removed by surgical methods, an  attempt 
must be made to intensif?. absorption with simultaneous 
excretion of the radiometal in order to prevent excessi\.e 
local radiation. Tliere can be no doubt tliat w e n  in 
this special case chelating agents are tlie most promising 
means. Appropriate experimental investigations into 
this problem ( I  9, 31, 40, 63) liave so far been limited 
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and carried out only with EDTA. They show, as does 
also analogous experience with man (64), that it is 
indeed possible in principle to intensify absorption in 
this way, but that the decontamination which is the 
final objective remains disappointingly slight, so that, 
first of all, it is not easy to decide whether the inherently 
low effectiveness of EDTA is to be blamed exclusively 
for tlie poor results obtained. The examination of DTPA 
which is a priori more effective seems therefore to be one 
of the most urgent tasks at the moment. In the special 
case of radiometals deposited in the respiratory tract, it 
would also be useful to test the effectiveness of a chelating 
agent administered in aerosol form. Exploratory tests by 
Semenov et al. (72) with this type of application have 
shown that EDTA is remarkably effective with radio- 
yttriurn. Both parenteral and oral administration of 
chelating agents seem to be contraindicated where 
radiometals are present in the digestive tract, since in 
some circurnstances they could increase parenteral ab- 
sorption of radiometals, and they may affect the effectiv- 
ity of other materials administered for the purpose of 
inhibiting absorption (e.g., ion exchangers). 
In conclusion we rnay deal briefly with the question 
of DTPA toxicity. As far as the decalcifying effects of 
Na3-DTPA and the toxicity of single doses of CaNa3- 
DTPA are concerned, exploratory tests (12, 23) suggest 
that the significant dosages are of the Same order as 
those of EDTA. From the point of view of practical 
therapeutic use, the experiments with animals (27, 80) 
and the corresponding clinical trials (64, 74) have shown 
the exceptional importance of the nephrotoxic effects of 
repeated doses of chelating agents. Such effects are the 
limiting factor as regards the administration of chelating 
agents over as short a time as possible, which is desirable 
in itself. The question whether the nephrotoxic effect of 
DTPA differs quantitatively from that of EDTA still 
remains Open. Since the exact cause of the kidney damage 
is still not clear (74), in our view, no a priori assertions 
can be made. Comparati\xe toxicological tests with 
DTPA and EDTA and the determination of their 
therapeutic range are therefore desirable. Not until we 
have these results will we be justified in recommending 
the clinical use of DTPA without any restrictions. 
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